Email this article 
USE OF PROSTATIC SPECIFIC ANTIGEN AS A PREDICTOR OF THE LONG-TERM RESULTS OF BRACHYTHERAPY FOR PROSTATE CANCER
- Authors: Ivanov S.A.1, Khmelevsky E.V.1, Fastovets S.V.1
-
Affiliations:
- Russian X-ray Radiology Research Center, Ministry of Health and Social Development of the Russian Federation
- Issue: Vol 5, No 4 (2009)
- Pages: 54-57
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS
- Published: 30.12.2009
- URL: https://oncourology.abvpress.ru/oncur/article/view/298
- DOI: https://doi.org/10.17650/1726-9776-2009-5-4-54-57
- ID: 298
Cite item
Full Text
Abstract
Brachytherapy is a high-tech, mini-invasive, and effective treatment modality for prostate cancer (PC). Interstitial radiation therapy is presently one of the standard treatments for PC. A constantly increasing interest in brachytherapy is attributable to higher morbidity and to a need for local therapy modalities. Preoperative prostatic specific antigen levels allow one to predict whether the disease can progress.
About the authors
S. A. Ivanov
Russian X-ray Radiology Research Center, Ministry of Health and Social Development of the Russian Federation
Author for correspondence.
Email: oncourolog@gmail.com
Russian Federation
E. V. Khmelevsky
Russian X-ray Radiology Research Center, Ministry of Health and Social Development of the Russian Federation
Email: oncourolog@gmail.com
Russian Federation
S. V. Fastovets
Russian X-ray Radiology Research Center, Ministry of Health and Social Development of the Russian Federation
Email: oncourolog@gmail.com
Russian Federation
References
Supplementary files
